OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial

ss Open Acce Oral presentation OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial D Salmon-Ceron*1,3, C Durier2, C Desaint10, Cuzin4, M Surenaud5, Y Henin10, J Lelievre6, B Bonnet7, G Pialoux8, I Poizot-Martin9, N Ben Hamouda5, A Jackson5, C Flys5, C Guerin10, J Aboulker2, J Choppin5 and O Launay10